CAJ | 학술논문

目的：探讨在常规冠心病药物治疗基础上联合应用尼可地尔对稳定性冠心病患者治疗效果。方法：入选100例确诊为稳定性冠心病住院患者，随机分为尼可地尔组（常规药物基础上加用尼可地尔5mg ，3次/d）和常规治疗组，各50例。出院后随访6个月，对比两组随访前后心绞痛发作频率，心电图、血清超敏C反应蛋白（hsCRP）以及6min步行试验结果。结果：随访6个月，与常规治疗组比较，尼可地尔组临床疗效（48％比74％）和心电图疗效（78％比96％）显著提高（ P均＜0.05）；两组的心绞痛发作频率、血清 hsCRP水平较随访前显著降低，6min步行距离显著增加， P均＜0.05；与常规治疗组比较，尼可地尔组心绞痛发作频率[（10.35±1.51）次/周比（9.95±1.65）次/周]、hsCRP水平[（1.12±0.51） mg/L比（0.95±0.43） mg/L]降低得更显著，6min步行距离[（342.38±35.64） m比（388.64±32.43） m ]显著增加（ P均＜0.05）。结论：尼可地尔可以有效地降低稳定性冠心病心绞痛的发作次数和血清超敏C反应蛋白水平，增加运动耐量，提高临床疗效。
목적：탐토재상규관심병약물치료기출상연합응용니가지이대은정성관심병환자치료효과。방법：입선100례학진위은정성관심병주원환자，수궤분위니가지이조（상규약물기출상가용니가지이5mg ，3차/d）화상규치료조，각50례。출원후수방6개월，대비량조수방전후심교통발작빈솔，심전도、혈청초민C반응단백（hsCRP）이급6min보행시험결과。결과：수방6개월，여상규치료조비교，니가지이조림상료효（48％비74％）화심전도료효（78％비96％）현저제고（ P균＜0.05）；량조적심교통발작빈솔、혈청 hsCRP수평교수방전현저강저，6min보행거리현저증가， P균＜0.05；여상규치료조비교，니가지이조심교통발작빈솔[（10.35±1.51）차/주비（9.95±1.65）차/주]、hsCRP수평[（1.12±0.51） mg/L비（0.95±0.43） mg/L]강저득경현저，6min보행거리[（342.38±35.64） m비（388.64±32.43） m ]현저증가（ P균＜0.05）。결론：니가지이가이유효지강저은정성관심병심교통적발작차수화혈청초민C반응단백수평，증가운동내량，제고림상료효。
Objective:To explore the therapeutic effect of nicorandil based on routine medication on stable coronary heart disease (CHD) .Methods :A total of 100 inpatients diagnosed as stable CHD were enrolled ,randomly and e-qually divided into nicorandil group (received nicorandil 5mg based on routine medication ,three times/d) and rou-tine treatment group .After discharge ,patients were followed up for six months .Angina pectoris frequency ,ECG , serum level of high sensitive C reactive protein (hsCRP) and 6min walking distance (6MWD) were compared be-tween two groups before and after follow up .Results:After six-month follow up ,compared with routine treatment group ,there were significant improvements in clinic therapeutic effect (48% vs .74% ) and ECG therapeutic effect (78% vs .96% ) in nicorandil group , P<0.05 all;compared with before follow-up ,there were significant reduc-tions in angina pectoris frequency and serum hsCRP level ;and significant rise in 6MWD in both groups , P<0.05 all;compared with routine treatment group ,there were significant reductions in angina pectoris frequency [ (10.35 ± 1.51) times/week vs .(9.95 ± 1.65) times/week] and hsCRP level [ (1.12 ± 0.51) mg/L vs .(0.95 ± 0.43) mg/L];and significant increase in 6MWD [ (342.38 ± 35.64) m vs .(388.64 ± 32.43) m] in nicorandil group , P<0.05 all .Conclusion:Nicorandil can effectively reduce the attack number of angina pectoris of stable coronary heart disease and serum hsCRP level ,increase exercise tolerance and improve clinical therapeutic effect .